Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Significance: Although antibodies can normally be obtained against a wide variety of antigens, there are still hard targets, including weakly immunogenic epitopes, which are not readily amenable to existing production techniques. In addition, such techniques can be relatively time-consuming and costly, especially if the screening for a specific epitope is required. In this work we describe a rational design method that enables one to obtain antibodies targeting any specific epitope within a disordered protein or disordered region. We show that this method can be used to target three disordered proteins and peptides associated with neurodegenerative and systemic misfolding diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BLAST+: architecture and applications
Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., & Madden, T. L. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-421 · Cited by 22,074 · cited 1×
“The blast search for the complementary peptides was carried out with the pblast program within the BLAST+ package (45) against the human reference proteome as downloaded from the UniProt website.”
AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR
Laskowski, R., Rullmann, J. A., MacArthur, M., Kaptein, R., & Thornton, J. (1996) · Journal of Biomolecular NMR · doi:10.1007/bf00228148 · Cited by 5,502 · cited 2×
“The best combination of CDR2/CDR3 lengths was selected with the PROCHECK-NMR program (49), as the one of the model that scored lower in equivalent resolution and in number of residues in disallowed regions of the Ramachandran maps.”
Intrinsically unstructured proteins and their functions
Dyson, H. J., & Wright, P. E. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1589 · Cited by 3,871
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The amyloid state and its association with protein misfolding diseases.
Knowles, T. P. J., Vendruscolo, M., & Dobson, C. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3810 · Cited by 2,382
Self-citationProtein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Intrinsic Disorder and Protein Function
Dunker, A. K., Brown, C. J., Lawson, J. D., Iakoucheva, L. M., & Obradović, Z. (2002) · Biochemistry · doi:10.1021/bi012159+ · Cited by 1,731
Making antibodies by phage display technology
Winter, G., Griffiths, A. D., Hawkins, R. E., & Hoogenboom, H. R. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002245 · Cited by 1,573
Intrinsic Disorder in Cell-signaling and Cancer-associated Proteins
Iakoucheva, L. M., Brown, C. J., Lawson, J. D., Obradović, Z., & Dunker, A. K. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00969-5 · Cited by 1,214
Flexible nets: The roles of intrinsic disorder in protein interaction networks
Dunker, A. K., Cortese, M. S., Romero, P., Iakoucheva, L. M., & Uversky, V. N. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.04948.x · Cited by 1,122
Cited by
Point-of-Care Diagnostics: Recent Developments in a Connected Age
Nayak, S., Blumenfeld, N. R., Laksanasopin, T., & Sia, S. K. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04630 · Cited by 508
Different soluble aggregates of Aβ42 can give rise to cellular toxicity through different mechanisms
De, S., Wirthensohn, D. C., Flagmeier, P., Hughes, C., Aprile, F. A., Ruggeri, F. S., Whiten, D. R., Emin, D., Xia, Z., Varela, J. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09477-3 · Cited by 448
Self-citationAtomically accurate de novo design of antibodies with RFdiffusion
Bennett, N. R., Watson, J. L., Ragotte, R. J., Borst, A. J., See, D. L., Weidle, C., Biswas, R., Yu, Y., Shrock, E. L., Ault, R., et al. (2024) · doi:10.1101/2024.03.14.585103 · Cited by 324
“Efforts at computational design of antibodies have grafted residues into existing antibody structures, sampled alternative native CDR loops to improve affinities 3,4 and used Rosetta 5 sequence design to improve the interacting regions.”
Atomically accurate de novo design of antibodies with RFdiffusion
(2025) · doi:10.1038/s41586-025-09721-5 · Cited by 324
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Fragment-based computational design of antibodies targeting structured epitopes
Aguilar Rangel, M., Bedwell, A., Costanzi, E., Taylor, R. J., Russo, R., Bernardes, G. J. L., Ricagno, S., Frydman, J., Vendruscolo, M., & Sormanni, P. (2022) · Science Advances · doi:10.1126/sciadv.abp9540 · Cited by 55
“In addition, the two top hits from the shortlisted CDR candidates (DesAbHSAP1 and DesAbHSAP2) were taken to be grafted directly into the CDR3 of a stable VHH scaffold (21).”
BackgroundSelf-citationLiu, X., Taylor, R. D., Griffin, L., Coker, S.-F., Adams, R., Ceska, T., Shi, J., Lawson, A. D. G., & Baker, T. (2017) · Scientific Reports · doi:10.1038/srep41306 · Cited by 39
Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology
Mingo, J., Luna, S., Gaafar, A., Nunes-Xavier, C. E., Torices, L., Mosteiro, L., Ruiz, R., Guerra, I., Llarena, R., Angulo, J. C., et al. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0083-4 · Cited by 22
Hallucinating structure-conditioned antibody libraries for target-specific binders
Mahajan, S. P., Ruffolo, J. A., Frick, R., & Gray, J. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999034 · Cited by 20
“The intrinsic solubility of the designed residues (padded with 10 residues on either end) was calculated with CamSol (56, 57).”
MethodBiosensing strategies for amyloid‐like protein aggregates
Zhou, Y., Yan, S., Dong, W., Wu, C., Zhao, Z., Wang, R., Duo, Y., Huang, Y., Xu, D., & Jiang, C. (2024) · BMEMat · doi:10.1002/bmm2.12053 · Cited by 16
Optimized optogenetic anti-CRISPR for endogenous gene regulation in Drosophila
Ramongolalaina, C., Pastor-Pareja, J. C., Zhang, E., & Jia, Y. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag244 · Cited by 1
Optimized optogenetic anti-CRISPR for endogenous gene regulation in Drosophila
Ramongolalaina, C., Pastor-Pareja, J. C., Zhang, E., & Jia, Y. (2025) · doi:10.1101/2025.05.02.651826 · Cited by 1
Metadata
- Authors
- Sormanni, P., Aprile, F. A., & Vendruscolo, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2015-07-27
- Volume
- 112
- Issue
- 32
- Pages
- 9902-9907
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1912933662
- Cited by
- 149
- References
- 15
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.